Herceptin functionalized polyhedral oligomeric silsesquioxane - conjugated oligomers - silica/iron oxide nanoparticles for tumor cell sorting and detection

Biomaterials

Volumn 32, Issue 32, 2011, Pages 8226-8233

  Mi, Yu ^a   Li, Kai ^a   Liu, Yutao ^a   Pu, Kan Yi ^a   Liu, Bin ^a   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer nanotechnology; Conjugated oligomers; CTC; Iron oxides; Silica nanoparticles; Trastuzumab

Indexed keywords

CANCER NANOTECHNOLOGY; CONJUGATED OLIGOMER; CTC; SILICA NANOPARTICLES; TRASTUZUMAB;

DISEASES; FLUORESCENCE; IRON OXIDES; MONOCLONAL ANTIBODIES; NANOPARTICLES; NONINVASIVE MEDICAL PROCEDURES; OLIGOMERS; ORGANIC COATINGS; SCAFFOLDS (BIOLOGY); SILICA; TUMORS;

NANOMAGNETICS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRON OXIDE; NANOPARTICLE; OLIGOMER; SILICON DIOXIDE; SILSESQUIOXANE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CELL SELECTION; CIRCULATING TUMOR CELL; CONJUGATION; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; NANOENGINEERING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; FERRIC COMPOUNDS; FLOW CYTOMETRY; FLUORESCENCE; HUMANS; MAGNETICS; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASTIC CELLS, CIRCULATING; NIH 3T3 CELLS; ORGANOSILICON COMPOUNDS; SILICON DIOXIDE; SURFACE PROPERTIES;

EID: 80052375294     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.040     Document Type: Article

References (35)

1. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1889, 1989(8):98-101.
2. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
3. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
4. Molnar B., Ladanyi A., Tanko L., Sreter L., Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001, 7:4080-4085.
5. Loberg R.D., Fridman Y., Pienta B.A., Keller E.T., McCauley L.K., Taichman R.S., et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 2004, 6:302-309.
6. Alunni-Fabbroni M., Sandri M.T. Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 2010, 50:289-297.
7. Dharmasiri U., Witek M.A., Adams A.A., Soper S.A. Microsystems for the Capture of low-abundance cells. Annu Rev Anal Chem 2010, 3:409-431.
8. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
9. Zabaglo L., Ormerod M.G., Dowsett M. Measurement of markers for breast cancer in a model system using laser scanning cytometry. Cytometry 2000, 41:166-171.
10. Bosma A.J., Weigelt B., Lambrechts A.C., Verhagen O.J.H.M., Pruntel R., Hart A.A.M., et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 2002, 8:1871-1877.
11. Helo P., Cronin A.M., Danila D.C., Wenske S., Gonzalez-Espinoza R., Anand A., et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with cell search assay and association with bone metastases and with survival. Clin Chem 2009, 55:765-773.
12. Nagrath S., Sequist L.V., Maheswaran S., Bell D.W., Irimia D., Ulkus L., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450. 1235-U10.
13. Adams A.A., Okagbare P.I., Feng J., Hupert M.L., Patterson D., Gottert J., et al. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J Am Chem Soc 2008, 130:8633-8641.
14. Wang S.T., Wang H., Jiao J., Chen K.J., Owens G.E., Kamei K.I., et al. Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Edit 2009, 48:8970-8973.
15. Saliba A.E., Saias L., Psychari E., Minc N., Simon D., Bidard F.C., et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. P Natl Acad Sci USA 2010, 107:14524-14529.
16. Pu K.Y., Li K., Zhang X.H., Liu B. Conjugated oligoelectrolyte harnessed polyhedral oligomeric silsesquioxane as light-up hybrid nanodot for two-photon fluorescence imaging of cellular nucleus. Adv Mater 2010, 22:4186.
17. Baney R.H., Itoh M., Sakakibara A., Suzuki T. Silsesquioxanes. Chem Rev 1995, 95:1409-1430.
18. Chan K.L., Sonar P., Sellinger A. Cubic silsesquioxanes for use in solution processable organic light emitting diodes (OLED). J Mater Chem 2009, 19:9103-9120.
19. Lee J.E., Lee N., Kim H., Kim J., Choi S.H., Kim J.H., et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc 2010, 132:552-557.
20. Yezhelyev M.V., Al-Hajj A., Morris C., Marcus A.I., Liu T., Lewis M., et al. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv Mater 2007, 19:3146.
21. Smith A.M., Duan H.W., Mohs A.M., Nie S.M. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliver Rev 2008, 60:1226-1240.
22. Zhang J., Campbell R.E., Ting A.Y., Tsien R.Y. Creating new fluorescent probes for cell biology. Nat Rev Mol Cell Bio 2002, 3:906-918.
23. Zhang C., Liu T., Su Y.P., Luo S.L., Zhu Y., Tan X., et al. A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for in vivo imaging. Biomaterials 2010, 31:6612-6617.
24. Koch A.M., Reynolds F., Kircher M.F., Merkle H.P., Weissleder R., Josephson L. Uptake and metabolism of a dual fluorochrome tat-nanoparticle in HeLa cells. Bioconjug Chem 2003, 14:1115-1121.
25. Pu K.Y., Li K., Liu B. Cationic oligofluorene-substituted polyhedral oligomeric silsesquioxane as light-harvesting unimolecular nanoparticle for fluorescence amplification in cellular imaging. Adv Mater 2010, 22:643.
26. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 2004, 100:247-256.
27. Brown K.C. Peptidic Tumor Targeting Agents: the road from phage display peptide selections to clinical applications. Curr Pharm Design 2010, 16:1040-1054.
28. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157.
29. Ahlgren S., Wallberg H., Tran T.A., Widstrom C., Hjertman M., Abrahmsen L., et al. Targeting of HER2-expressing tumors with a site-specifically Tc-99m-labeled recombinant affibody molecule, Z(HER2:2395), with C-terminally engineered cysteine. J Nucl Med 2009, 50:781-789.
30. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001, 344:783-792.
31. Hudis C.A. Drug therapy: trastuzumab - mechanism of action and use in clinical practice. New Engl J Med 2007, 357:39-51.
32. Muller V., Witzel I., Stickeler E. Immunological approaches in the treatment of metastasized breast cancer. Breast Care 2009, 4:358-366.
33. Senter P.D. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009, 13:235-244.
34. Park J., An K.J., Hwang Y.S., Park J.G., Noh H.J., Kim J.Y., et al. Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater 2004, 3:891-895.
35. Wiig H., Gyenge C.C., Tenstad O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol-London 2005, 567:557-567.